Product
Meeting
Title
CBP-1008
ASCO 2023
Poster: First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
Abstract: First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
ASCO 2022
Presentation: A Phase Ia/Ib Study of CBP-1008, a Bi-specific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors
Abstract: A Phase Ia/Ib Study of CBP-1008, a Bi-specific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors
CBP-1018
ESMO 2023
Poster: CBP-1018, a Bi-Ligand-Drug Conjugate treated in Patients with Advanced Solid Tumors: A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose Expansion Study
Abstract: CBP-1018, a Bi-Ligand-Drug Conjugate treated in Patients with Advanced Solid Tumors: A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose Expansion Study
Next-Generation Conjugates Summit 2023
Abstract: A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors
Poster: An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors
Abstract: An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors
CBP-8088
AACR 2024
Poster: CBP-8008: A first-in-class targeted pan-Bet protein degradation therapy using bi-specific XDC (Bi-XDC) conjugate for TNBC and mCRPC
